Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc.verified

DCPH

Price:

$25.46

Market Cap:

$2.20B

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to ...[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2017-09-28

Stock Exchange

NASDAQ

Ticker

DCPH

The PE Ratio as of May 2024 (TTM) for Deciphera Pharmaceuticals, Inc. (DCPH) is -11.52

According to Deciphera Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -11.52. This represents a change of 72.51% compared to the average of -6.68 of the last 4 quarters.

Deciphera Pharmaceuticals, Inc. (DCPH) Historical PE Ratio (quarterly & annually)

How has DCPH PE Ratio performed in the past?

The mean historical PE Ratio of Deciphera Pharmaceuticals, Inc. over the last ten years is -9.95. The current -11.52 PE Ratio has changed 11.47% with respect to the historical average. Over the past ten years (40 quarters), DCPH's PE Ratio was at its highest in in the September 2017 quarter at -0.81. The PE Ratio was at its lowest in in the June 2018 quarter at -15.22.

Quarterly (TTM)
Annual

Average

-9.95

Median

-7.57

Minimum

-18.61

Maximum

-1.91

Deciphera Pharmaceuticals, Inc. (DCPH) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Deciphera Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 261.75%

Maximum Annual PE Ratio = -1.91

Minimum Annual Increase = -84.00%

Minimum Annual PE Ratio = -18.61

Quarterly (TTM)
Annual
YearPE RatioChange
2023-7.041.77%
2022-6.92261.75%
2021-1.91-84.00%
2020-11.95-14.27%
2019-13.9387.30%
2018-7.44-1.73%
2017-7.57-46.76%
2016-14.22-23.61%

Deciphera Pharmaceuticals, Inc. (DCPH) Average PE Ratio

How has DCPH PE Ratio performed in the past?

The current PE Ratio of Deciphera Pharmaceuticals, Inc. (DCPH) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-5.29

5-year avg

-8.35

10-year avg

-9.95

Deciphera Pharmaceuticals, Inc. (DCPH) PE Ratio vs. Peers

How is DCPH’s PE Ratio compared to its peers?

Deciphera Pharmaceuticals, Inc.’s PE Ratio is less than Eagle Pharmaceuticals, Inc. (3.27), less than ANI Pharmaceuticals, Inc. (33.01), less than Phibro Animal Health Corporation (56.56), less than Prestige Consumer Healthcare Inc. (15.39), less than Evotec SE (-10.12), greater than Supernus Pharmaceuticals, Inc. (-102.83), less than Collegium Pharmaceutical, Inc. (11.25), less than Neurocrine Biosciences, Inc. (38.41), less than Ironwood Pharmaceuticals, Inc. (-0.97), less than Alkermes plc (9.34), less than Avadel Pharmaceuticals plc (-9.06), less than Amphastar Pharmaceuticals, Inc. (13.55), less than Procaps Group S.A. (5.15), less than Silver Spike Investment Corp. (13.99),

Build a custom stock screener for Deciphera Pharmaceuticals, Inc. (DCPH) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Deciphera Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Deciphera Pharmaceuticals, Inc. (DCPH) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Deciphera Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Deciphera Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Deciphera Pharmaceuticals, Inc. (DCPH)?

What is the highest PE Ratio for Deciphera Pharmaceuticals, Inc. (DCPH)?

What is the 3-year average PE Ratio for Deciphera Pharmaceuticals, Inc. (DCPH)?

What is the 5-year average PE Ratio for Deciphera Pharmaceuticals, Inc. (DCPH)?

How does the current PE Ratio for Deciphera Pharmaceuticals, Inc. (DCPH) compare to its historical average?